Whooping Cough Clinical Trial
Official title:
Retail Pharmacy Vouchers to Promote Tdap Vaccination for Adults Living With Infants
This study is a small-scale randomized, placebo-controlled factorial trial of two interventions to increase Tetanus, diphtheria and acellular pertussis (Tdap) immunization rates among infant caregivers. Specifically, the trial will compare a full cost vs. $5 Tdap voucher with or without an educational video.
The incidence of pertussis, a highly contagious respiratory illness, has more than tripled
in the past five years, and is on track this year to be the most severe in over a half
century. Pertussis is particularly dangerous, and commonly fatal, for young infants who have
not completed the primary vaccination series. To protect infants, pregnant women and adult
caregivers should receive Tdap vaccination, but coverage is estimated at only 10% for adult
caregivers in close contact with infants.
The objective of this study is to conduct a small-scale randomized controlled trial of an
intervention to increase Tdap immunization rates among infant caregivers. The intervention
is delivered at the newborn primary care visit and consists of two components: (1) Tdap
vaccine vouchers redeemable at neighborhood retail pharmacies and (2) video-based education.
The vouchers improve vaccine supply by reducing cost and improving accessibility of the
vaccine, while the education component increases demand for the vaccine by making salient
the dangers of pertussis and the importance adult vaccination to "cocoon" vulnerable
infants. We will evaluate the feasibility and acceptability of each component or both
compared to none and assess the impact on the vaccination of parents/caregivers of newborn
infants.
Recruitment for this pilot study will take place at a pediatric primary care practice site
affiliated with a large children's hospital in Philadelphia, Pennsylvania (PA). The practice
schedules approximately 135 newborn visits per month, typically at 2-14 days of life.
Participants will redeem Tdap vaccine vouchers at 2 local Rite Aid pharmacies which are the
closest Rite Aid locations to the clinic site. The pharmacy accepts all major insurance
plans, although most plans (including Medicaid) do not cover Tdap vaccine delivered in
pharmacies.
All caregivers ≥ 18 years old who accompany an infant to a newborn visit will be approached
by the study coordinator and details of the study will be explained. Caregivers will be
asked to participate in the study and if interested, informed consent will be obtained
before any study related procedures are performed. Potential subjects will then be screened
using the protocol inclusion and exclusion criteria. The research assistant will utilize a
data collection form to collect demographic data. After completion of the data collection
form, participants will view an educational video if randomized to the education arm. After
viewing the educational video, or after completion of data collection form for those who
were not randomized to video, participants will receive an envelope containing the Tdap and
baby care item voucher or gift card.
Unvaccinated caregivers will receive an envelope containing 2 vouchers or a voucher and a
gift card. The vouchers are: one for Tdap vaccination and one for a baby care item. Vouchers
will be redeemable only at the two participating nearby Rite Aid pharmacies, will have no
monetary value, and cannot be redeemed for any items other than the specified vaccine/baby
care product.The gift card can be redeemed at any Rite Aid pharmacy.All envelopes will also
contain the Center for Disease Control and Prevention (CDC) Vaccine Information Sheet
(V.I.S) for the Tdap vaccine. Participants will be randomized to receive either: (1) a
voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher/or gift
card, or (2) a voucher for $5 off a Tdap vaccine + a baby care product voucher/or gift card.
The baby care product voucher / gift card will allow us to assess the proportion of
respondents who make a trip to one of the pharmacies following the primary care visit and
may also increase the probability that the study participants will visit one of the
designated retail pharmacies. The full cost voucher removes any cost barriers related to the
Tdap vaccine. The $5 voucher allows us to assess the effect of increased awareness,
convenience, and accessibility on vaccine uptake, but without a significant price change. If
two unvaccinated caregivers accompany an infant and both choose to enroll in the study, they
may receive discordant Tdap voucher amounts; however, both will receive baby care product
vouchers / gift cards.
Randomization to each arm will occur through block randomization of study numbers that will
take place prior to recruitment. The research assistants will show the video and will
therefore not be blinded to educational arm. However, research assistants who enroll
participants will be blinded to voucher arm as envelopes will be sealed. Research staff will
enter the study number on the data collection form but only the principal investigator and
study coordinator will have access to the master file indicating allocation to intervention
group.
Voucher redemption is voluntary; data regarding vaccination redemption will be collected by
Rite Aid pharmacies. Participants who choose to redeem Tdap vaccine vouchers can do so, at
their convenience, at 2 local Rite Aid pharmacies. At the pharmacy, the caregiver must
complete a screening form before receiving Tdap. Vouchers are serialized with a barcode
which is swiped at the time of redemption Baby care item vouchers will be like a coupon and
can be redeemed by a cashier at the pharmacy.
Project staff will perform phone follow-up interviews with participants one month after they
were enrolled in the study to ascertain vaccination status and to solicit feedback on the
intervention and barriers to vaccination.
Baseline characteristics will be summarized by standard descriptive summaries (e.g. means
and standard deviations for continuous variables and percentages for categorical variables).
All vouchers will have unique identification (ID) numbers. Variables such as age, gender,
insurance status, the relationship of the participant(s) to the infant, vaccination status,
and the date and time of the voucher distribution will be summarized. The research
coordinator will also record how many caregivers refuse to participate or are not approached
for enrollment. The proportion of caregivers screened that meet enrollment criteria and the
proportion meeting enrollment criteria that consent to participate will be calculated.
We will measure the proportion of participants enrolled that redeemed a study Tdap voucher.
In addition, we will assess the feasibility of voucher distribution, the completeness of
redemption data recorded at the pharmacy, and the ability to assess caregiver vaccination
status. Vaccination status will be determined by self-report at the time of enrollment and
at the time of the follow-up interview. Vaccination rates will also be measured by Tdap
voucher redemption. We will measure the redemption rate of the Tdap voucher by treatment arm
($5 voucher vs. full-cost voucher, and video vs. no video), adjusting for sociodemographic
characteristics. We will also determine the proportion of baby care product vouchers / gift
cards redeemed by treatment arm.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03035370 -
Viaskin Pertussis Vaccine Trial
|
Phase 1 | |
Completed |
NCT02453048 -
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
|
Phase 1 | |
Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
Active, not recruiting |
NCT05091619 -
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
|
Phase 3 | |
Completed |
NCT02587520 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01983540 -
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
|
Phase 3 | |
Completed |
NCT01545115 -
Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal
|
N/A | |
Recruiting |
NCT04238975 -
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
|
Phase 2 | |
Completed |
NCT01439165 -
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
|
Phase 4 | |
Recruiting |
NCT03751514 -
Bordetella Pertussis Colonisation Challenge Study
|
N/A | |
Active, not recruiting |
NCT01279668 -
Montelukast for Persistent Cough in Young People and Adults
|
Phase 4 | |
Completed |
NCT00337428 -
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00662870 -
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
|
Phase 3 | |
Completed |
NCT01529645 -
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
|
Phase 1 | |
Recruiting |
NCT04036526 -
A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02813486 -
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
|
Phase 1/Phase 2 | |
Completed |
NCT01629589 -
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
|
Phase 4 | |
Completed |
NCT03942406 -
Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
|
Phase 2 | |
Completed |
NCT03137927 -
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
|
Phase 1 | |
Completed |
NCT02301702 -
Maternal Tdap Immunization in Guatemala
|
Phase 2 |